Dr. Carl Nathan and colleagues will study the genetic mechanism by which tuberculosis emerges from its latent state into an infectious and symptomatic disease.
Tuberculosis is a major cause of death around the world, with as many as one-third of the world's population infected with the bacterium, among whom about 16 million develop the disease each year and more than 1.6 million succumb, mainly in developing countries. The majority of those infected have a clinically latent infection; that is, they test positive for the bacterium but are asymptomatic and not contagious. However, 5 to 10 percent of this latent group will develop tuberculosis, becoming symptomatic and infectious.
"Understanding how the mycobacterium resumes replication will be key to reducing the prevalence of latent infection to break the cycle of TB transmission," says Dr. Nathan, who is chairman of the Department of Microbiology and Immunology, R.A. Rees Pritchett Professor of Microbiology and director of the Abby and Howard P. Milstein Program in Chemical Biology of Infectious Disease at Weill Cornell Medical College.
"I congratulate each individual who took the initiative to share their idea with us to help fight the world's most serious diseases," says Dr. Tachi Yamada, president of the Gates Foundation's Global Health Program. "The number of creative approaches we received exceeded our highest aspirations. Projects from this initial pool of grants have the potential to transform health in developing countries, and I will be rooting for their success."
'/>"/>
| Contact: Andrew Klein ank2017@med.cornell.edu 212-821-0560 New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College Source:Eurekalert |